Wegovy pill dosage: separating fact from assumption

The biggest misconception: the Wegovy pill dose is not the same as the injection dose

The most common question arriving in our prescribers' inboxes right now is some version of: "The injection goes up to 2.4 mg, so why does the tablet go to 25 mg?" Reasonable question. The explanation lies in absorption. Oral semaglutide is poorly absorbed across the gut wall on its own, so the tablet contains an absorption enhancer called SNAC, which temporarily alters the local stomach environment to let the drug through. Even with SNAC, a far smaller fraction of the dose reaches the bloodstream compared to a subcutaneous injection, which is why the tablet numbers look so much larger. The active medicine doing the work at 25 mg daily is delivering broadly similar exposure to semaglutide 2.4 mg weekly injected. They are not different medicines; the delivery route demands a different scale.

The second misconception worth correcting immediately: the Wegovy weight-loss tablet is not Rybelsus. Rybelsus is also oral semaglutide, but it comes in 3 mg, 7 mg and 14 mg tablets and is licensed exclusively for type 2 diabetes. If you see those strengths mentioned in the context of weight loss, the page you are reading has confused the two products. If you want to understand exactly how the Wegovy oral dose is structured and why it differs from those diabetes strengths, we cover that in full detail. The Wegovy tablet dosing steps are 1.5 mg, 4 mg, 9 mg and 25 mg, and those are the only four that matter here.

You can read more about how semaglutide tablets compare to the injection in terms of mechanism and eligibility.

The four steps: what happens at each rung of the schedule

The schedule is designed to reduce gastrointestinal side effects during the period your body adjusts. Starting at 1.5 mg for a minimum of one month gives your gut time to adapt before the dose moves up. From there, the steps are 4 mg, then 9 mg, then 25 mg, each held for at least a month. Your prescriber sets the pace; there is no fixed date on which you automatically move up, and some people spend longer at intermediate doses if their body needs it. The prescriber decides, not a calendar.

One detail that catches people out: if you are already established on the 2.4 mg weekly injection, clinical guidance allows a move directly to the 25 mg tablet, subject to assessment. The graduated titration is not repeated from scratch in that scenario, though your prescriber will still want to review your current status before confirming that switch. For a more detailed look at how the full titration plays out week by week, including semaglutide pill dosage for weight loss broken down stage by stage, the oral semaglutide dosage chart is a useful reference.

The MHRA approval announcement and the SmPC on the electronic Medicines Compendium (eMC) are the authoritative sources for exact dosing language; the summary here is factual but always defer to your prescriber and the patient leaflet for your own treatment.

How to take it: the 30-minute window matters more than most people expect

If you are wondering why the instructions are so specific about the morning routine, this is why: even a cup of coffee taken before the 30-minute window closes measurably reduces absorption. The tablet needs a near-empty stomach and a small amount of plain water (up to about 120 ml) to let SNAC do its job. Swallow it whole, sit upright, and wait. Other oral medicines taken in that window may also be affected, so let your prescriber know everything you take in the morning, including supplements.

This is also where the oral tablet diverges most practically from the injection. There is no needle, no refrigerator, no sharps bin to manage. The tablet lives at room temperature. For people who were hesitant about self-injecting, that difference is significant, and it is one reason access to the Wegovy pill in the UK is generating genuine interest since the MHRA approval in June 2026.

For context on how this fits within the broader landscape of weight-loss options, the weight-loss treatments overview sets out the full range of licensed medicines available through nume.

What the trial results mean for you, and what they do not promise

The OASIS 4 phase 3 trial followed 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks. On average, participants lost around 13.6% of body weight compared with about 2.4% in the placebo group. Among those who stuck fully to treatment, the figure reached approximately 17%. Both are real, both are cited honestly, and neither is a guarantee for any individual. Weight-loss medicines work alongside a reduced-calorie diet and increased activity, not instead of them. People respond differently, which is precisely why a prescriber reviews your history before starting you on any dose.

The most common side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported more often than placebo. In most cases they were mild to moderate and eased as the body adjusted, particularly after spending longer at lower dose steps before moving up. Persistent or severe symptoms (especially stomach pain that radiates to the back) should prompt a call to your healthcare team promptly.

If you are comparing this to the injection or weighing up which format might suit your lifestyle, the page on oral semaglutide dosing for non-diabetics covers the eligibility and clinical nuances in more detail. And if you are ready to talk through whether the Wegovy tablet is right for you specifically, starting a free consultation is the natural next step, a GPhC-registered prescriber will review your details the same day.